Citi analyst Eric Joseph initiated coverage of BridgeBio (BBIO) with a Neutral rating and $82 price target The firm sees the shares as range-bound in the medium term with the company’s pipeline “mostly operational” into the end of 2026. Citi views the 2026 expectations for Attruby as achievable.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO: